March 9 - Agilent Technologies said on Monday it has reached an agreement to acquire Biocare Medical in an all-cash transaction valued at $950 million. The buyer will acquire California-based Biocare from private equity sellers Excellere Partners and GHO Capital Partners, and expects the purchase to be completed by Agilent’s fourth fiscal quarter of 2026.
Under the terms announced, Biocare will be integrated into Agilent’s Life Sciences and Diagnostics Markets unit. Biocare is a privately held clinical pathology company whose product set centers on integrated tissue diagnostic tools used in the detection and characterization of cancer and infectious disease. The company’s website also identifies government and military laboratories among its listed customers.
Agilent reported first-quarter results in February that were largely in line with estimates, which the company said signaled stable demand for its medical instruments and related equipment. Agilent’s market capitalization stood at $33.38 billion, according to LSEG data cited in the announcement.
The transaction is structured as an all-cash purchase for the privately held firm and the parties said they anticipate closing by the fourth fiscal quarter of 2026. Until that closing occurs, Biocare remains owned by Excellere Partners and GHO Capital Partners.
Separately, the announcement noted that ProPicks AI evaluates Agilent - referenced by the ticker A in the original announcement - alongside thousands of other companies using over 100 financial metrics. The description included that the AI assesses fundamentals, momentum, and valuation to identify stocks that fit particular risk-reward profiles, and noted examples of past winners mentioned in the original text.
Context and implications
- Biocare’s product portfolio—integrated tissue diagnostics for cancer and infectious disease—is a direct fit with Agilent’s Life Sciences and Diagnostics Markets unit.
- The sellers named are Excellere Partners and GHO Capital Partners; until the anticipated closing in fiscal Q4 2026 the ownership structure remains unchanged.
- Agilent’s recent first-quarter performance, reported in February, was described as largely in line with estimates, indicating stable demand for its tools and equipment.